Comparative Pharmacology
Head-to-head clinical analysis: INVEGA HAFYERA versus SEZABY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA HAFYERA versus SEZABY.
INVEGA HAFYERA vs SEZABY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone palmitate is an atypical antipsychotic that antagonizes D2 and 5-HT2A receptors, with additional antagonism at alpha2, alpha1, and H1 receptors.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
INVEGA HAFYERA (paliperidone palmitate) is dosed once weekly via intramuscular injection in the gluteal or deltoid muscle. The recommended starting dose is 1,092 mg (deltoid or gluteal) or 1,560 mg (gluteal only) on treatment day 1 and day 8, both given in the deltoid muscle. Subsequent maintenance doses are administered once monthly. Note: INVEGA HAFYERA is only for once-weekly administration; once-monthly formulations (INVEGA SUSTENNA) are also available.
58 mg subcutaneously once monthly (every 30 days).
None Documented
None Documented
Terminal elimination half-life is 25-49 days (mean ~36 days) due to slow dissolution from intramuscular depot. Steady-state reached after 4-5 monthly injections.
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Primarily renal: 59% of paliperidone excreted unchanged in urine; 32% as metabolites; 6-12% fecal. Biliary excretion is minimal.
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic